Ludovico Messineo1, Roberto Magri2, Luciano Corda2, Laura Pini2, Luigi Taranto-Montemurro3, Claudio Tantucci2. 1. Respiratory Medicine and Sleep Laboratory, Department of Experimental and Clinical Sciences, University of Brescia and Spedali Civili, Piazzale Spedali Civili 1, 25000, Brescia, Italy. ludovico.messineo@yahoo.it. 2. Respiratory Medicine and Sleep Laboratory, Department of Experimental and Clinical Sciences, University of Brescia and Spedali Civili, Piazzale Spedali Civili 1, 25000, Brescia, Italy. 3. Division of Sleep and Circadian Disorders, Departments of Medicine and Neurology, Brigham & Women's Hospital & Harvard Medical School, Boston, MA, USA.
Abstract
BACKGROUND: Obstructive sleep apnea is a common disorder characterized by multiple pathogenetic roots. Continuous positive airway pressure (CPAP) is almost always prescribed as the first-line treatment to all patients regardless of the heterogeneous pathophysiology, because it mechanically splints the airways open and reduces the collapsibility of the upper airway. Despite its high efficacy, CPAP is burdened by poor adherence and compliance rates. In this pilot study, we treated OSA patients with composite approaches different than CPAP, tailoring the therapeutic choice on OSA phenotypic traits. METHODS: We used the CPAP dial down technique to assess phenotypic traits in eight OSA patients with BMI<35. According to these traits, patients received personalized therapies for 2-week period, after which we ran a second polygraphy to compare apnea-hypopnea index (AHI) before and after therapy. RESULTS: Two weeks of combined behavioral and pharmacological therapy induced a significant reduction in mean AHI, which dropped from 26 ± 15 at baseline to 9 ± 7 post-treatment (p = 0.01). Furthermore, there was a significant reduction in mean ODI (p = 0.03) and subjective sleepiness (p = 0.01) documented by Epworth Sleepiness Scale (ESS) from baseline to post-treatment recordings. CONCLUSIONS: Treating OSA patients with a personalized combination of pharmacological and behavioral therapies according to phenotypic traits leads to a significant improvement in AHI, ODI, and subjective sleepiness.
BACKGROUND: Obstructive sleep apnea is a common disorder characterized by multiple pathogenetic roots. Continuous positive airway pressure (CPAP) is almost always prescribed as the first-line treatment to all patients regardless of the heterogeneous pathophysiology, because it mechanically splints the airways open and reduces the collapsibility of the upper airway. Despite its high efficacy, CPAP is burdened by poor adherence and compliance rates. In this pilot study, we treated OSA patients with composite approaches different than CPAP, tailoring the therapeutic choice on OSA phenotypic traits. METHODS: We used the CPAP dial down technique to assess phenotypic traits in eight OSA patients with BMI<35. According to these traits, patients received personalized therapies for 2-week period, after which we ran a second polygraphy to compare apnea-hypopnea index (AHI) before and after therapy. RESULTS: Two weeks of combined behavioral and pharmacological therapy induced a significant reduction in mean AHI, which dropped from 26 ± 15 at baseline to 9 ± 7 post-treatment (p = 0.01). Furthermore, there was a significant reduction in mean ODI (p = 0.03) and subjective sleepiness (p = 0.01) documented by Epworth Sleepiness Scale (ESS) from baseline to post-treatment recordings. CONCLUSIONS: Treating OSA patients with a personalized combination of pharmacological and behavioral therapies according to phenotypic traits leads to a significant improvement in AHI, ODI, and subjective sleepiness.
Entities:
Keywords:
Alternative treatment for sleep apnea; OSA behavioral therapy; OSA pharmacological therapy; OSA phenotyping
Authors: Bradley A Edwards; Scott A Sands; Robert L Owens; Danny J Eckert; Shane Landry; David P White; Atul Malhotra; Andrew Wellman Journal: Sleep Date: 2016-11-01 Impact factor: 5.849
Authors: Bradley A Edwards; James G Connolly; Lisa M Campana; Scott A Sands; John A Trinder; David P White; Andrew Wellman; Atul Malhotra Journal: Sleep Date: 2013-02-01 Impact factor: 5.849
Authors: Danny J Eckert; David P White; Amy S Jordan; Atul Malhotra; Andrew Wellman Journal: Am J Respir Crit Care Med Date: 2013-10-15 Impact factor: 21.405
Authors: Eric J Kezirian; George S Goding; Atul Malhotra; Fergal J O'Donoghue; Gary Zammit; John R Wheatley; Peter G Catcheside; Philip L Smith; Alan R Schwartz; Jennifer H Walsh; Kathleen J Maddison; David M Claman; Tod Huntley; Steven Y Park; Matthew C Campbell; Carsten E Palme; Conrad Iber; Peter R Eastwood; David R Hillman; Maree Barnes Journal: J Sleep Res Date: 2013-09-04 Impact factor: 3.981
Authors: Ludovico Messineo; Luigi Taranto-Montemurro; Ali Azarbarzin; Melania D Oliveira Marques; Nicole Calianese; David P White; Andrew Wellman; Scott A Sands Journal: J Physiol Date: 2018-07-06 Impact factor: 5.182
Authors: Ritaban Dutta; Gary Delaney; Barbara Toson; Amy S Jordan; David P White; Andrew Wellman; Danny J Eckert Journal: Ann Am Thorac Soc Date: 2021-04
Authors: Eysteinn Finnsson; Guðrún H Ólafsdóttir; Dagmar L Loftsdóttir; Sigurður Æ Jónsson; Halla Helgadóttir; Jón S Ágústsson; Scott A Sands; Andrew Wellman Journal: Sleep Date: 2021-01-21 Impact factor: 6.313